Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews' Q3 Revenues Fall, Net Loss Climbs

NEW YORK (GenomeWeb News) - GeneNews today said third-quarter revenues tumbled as R&D spending was stable and net loss swelled 43 percent.
 
Total receipts for the three months ended Sept. 30 decreased to CA$189,000 (US$204,000) from CA$878,000 year over year.
 
The Toronto-based company said the only source of its revenue in 2007 so far stems from a CA$2 million agreement with an Asian biomedical consortium to identify and validate biomarkers for prostate disease. The company’s 2006 revenue came from a collaboration with Pfizer, which ran its course in the first quarter of 2007. 
 
R&D spending was flat at around CA$2.3 million.
 
Net loss increased to CA$3 million from CA$2.1 million in the year-ago period.
 
GeneNews said it had around CA$13 million in cash and cash equivalents as of Sept. 30.
 
The company, which is focused on biomarker research and development for diagnostic products, did not offer revenue projections for the full year.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.